T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1901
Wolverine World Wide
WWW
$1.63B
| $1.45M | ﹤0.01% |
80,049
-492
| -0.6% | -$9.94K |
|
1902
Center Bancorp
CNOB
$1.81B
| $1.44M | ﹤0.01% |
55,032
+1,935
| +4% | +$49K |
|
1903
Columbia Sportswear
COLM
$2.88B
| $1.44M | ﹤0.01% |
26,134
+880
| +3% | +$47K |
|
1904
Teladoc Health
TDOC
$1.26B
| $1.44M | ﹤0.01% |
204,905
+26,019
| +15% | +$204K |
|
1905
Amplitude
AMPL
$1.66B
| $1.43M | ﹤0.01% |
123,062
-89,190
| -42% | -$938K |
|
1906
Axogen
AXGN
$2.58B
| $1.43M | ﹤0.01% |
43,555
+2,894
| +7% | +$71.2K |
|
1907
Papa John's
PZZA
$804M
| $1.43M | ﹤0.01% |
37,005
+1,242
| +3% | +$54.9K |
|
1908
Edgewise Therapeutics
EWTX
$4.69B
| $1.42M | ﹤0.01% |
57,315
+5,929
| +12% | +$119K |
|
1909
James Hardie Industries
JHX
$17.9B
| $1.42M | ﹤0.01% |
68,472
+6,751
| +11% | +$135K |
|
1910
Protolabs
PRLB
$2.21B
| $1.42M | ﹤0.01% |
28,034
+798
| +3% | +$40.8K |
|
1911
Univest Financial
UVSP
$1.18B
| $1.42M | ﹤0.01% |
43,218
+815
| +2% | +$25.5K |
|
|
PRA
1912
DELISTED
ProAssurance
PRA
| $1.41M | ﹤0.01% |
58,471
+1,530
| +3% | +$36.8K |
|
1913
ACV Auctions
ACVA
$1.35B
| $1.41M | ﹤0.01% |
175,825
+27,012
| +18% | +$219K |
|
1914
Vertex
VERX
$2.15B
| $1.41M | ﹤0.01% |
70,642
+14,037
| +25% | +$304K |
|
1915
Middlesex Water
MSEX
$1.1B
| $1.41M | ﹤0.01% |
27,875
+3,619
| +15% | +$195K |
|
1916
Genius Sports
GENI
$2.2B
| $1.4M | ﹤0.01% |
127,403
+7,159
| +6% | +$78.1K |
|
1917
Arcus Biosciences
RCUS
$3.67B
| $1.4M | ﹤0.01% |
58,649
+9,307
| +19% | +$190K |
|
1918
Azenta
AZTA
$1.47B
| $1.4M | ﹤0.01% |
42,000
+2,871
| +7% | +$93.8K |
|
|
LADR
1919
Ladder Capital
LADR
$1.27B
| $1.4M | ﹤0.01% |
126,887
+3,810
| +3% | +$41.4K |
|
1920
Sally Beauty Holdings
SBH
$1.55B
| $1.4M | ﹤0.01% |
97,804
+4,347
| +5% | +$65.5K |
|
1921
Arbor Realty Trust
ABR
$981M
| $1.39M | ﹤0.01% |
179,521
+20,532
| +13% | +$201K |
|
1922
Wendy's
WEN
$1.65B
| $1.39M | ﹤0.01% |
166,902
+16,774
| +11% | +$145K |
|
1923
Winnebago Industries
WGO
$915M
| $1.39M | ﹤0.01% |
34,303
+3,856
| +13% | +$141K |
|
|
STEL
1924
DELISTED
Stellar Bancorp
STEL
| $1.39M | ﹤0.01% |
44,867
+3,755
| +9% | +$115K |
|
1925
J&J Snack Foods
JJSF
$1.7B
| $1.39M | ﹤0.01% |
15,339
+687
| +5% | +$62.3K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.